---
document_datetime: 2025-03-17 15:30:10
document_pages: 12
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/uptravi-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
document_name: uptravi-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
version: success
processing_time: 8.9286399
conversion_datetime: 2025-12-24 16:31:36.375076
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Uptravi

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------|
| II/0045              | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 16/01/2025                          | n/a                                         |                                  |                                                                           |
| II/0042/G            | This was an application for a group of variations.                                                                                            | 19/12/2024                          |                                             | SmPC and PL                      | SmPC new text As a result of the submission of peadiatric studies Section |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| A grouped application Variations as follows: C.I.4: Update of order to update on results from the this is a phase 2 study to evaluate the pharmacokinetics of years to less than 18 arterial hypertension C.I.4: Update of sections order to update efficacy based on results from study this is a phase 3 multicenter, randomized, placebo-controlled, with open-label extension efficacy and safety of selexipag standard of care in children 18 years of age with pulmonary (PAH). C.I.4: Update of sections order to update efficacy from the pharmacodynamic similarity/comparison study clinical responses for efficacy 065A203, study AC-065A310 in paediatric participants 18 years of age and adult The Package Leaflet is addition, the MAH took   | comprised sections 4.2 pharmacokinetic paediatric multicenter, safety, selexipag years of (PAH).   | 4.2, 5.1 and 5.2 of the SmPC have been updated to inform that currently available interim data are described in sections 5.1 and 5.2, but no recommendation on a posology can be made. Administration of selexipag in the paediatric population is not recommended. For more information, please refer to the Summary of Product Characteristics.   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                                  |                                                                                                                                            |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10503 /202312 | Periodic Safety Update EU Single assessment - selexipag                                                                                                                                                                                                                                                                                                 | 19/09/2024 | 14/11/2024 | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10503/202312. |
| IB/0044             | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                  | 24/04/2024 | n/a        |                                  |                                                                                                                                            |
| X/0038              | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                              | 25/01/2024 | 27/03/2024 | SmPC, Annex II, Labelling and PL |                                                                                                                                            |
| IB/0041             | B.II.b.5.f - Change to in-process tests or limits applied during the manufacture of the finished product - Addition or replacement of an in-process test as a result of a safety or quality issue                                                                                                                                                       | 12/03/2024 | n/a        |                                  |                                                                                                                                            |
| IB/0040             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                               | 06/12/2023 | 27/03/2024 | SmPC, Labelling and PL           |                                                                                                                                            |
| II/0039             | B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting                                                                                                                                                                                                                                                                     | 12/10/2023 | n/a        |                                  |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | material/intermediate/reagent - Change outside the approved specifications limits range for the AS                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0035   | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                               | 07/07/2022 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IB/0037/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor                                                                                                    | 06/07/2022 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0034   | Update of sections 4.8 and 5.1 of the SmPC to add dyspepsia as a new ADR with frequency common, and to include further information on the frequency of dyspepsia and on haemoglobin decrease in patients receiving triple combination therapy, and to add efficacy and mortality data of initial triple combination treatment with selexipag, macitentan and tadalafil in newly diagnosed PAH patients compared to initial double combination treatment with placebo, macitentan and tadalafil, based on the | 19/05/2022 | 04/07/2023 | SmPC and PL | Update of the SmPC section 5.1: In a double blind, placebo-controlled study, a total of 247 newly diagnosed PAH patients were randomised to evaluate the treatment effect of initial triple (selexipag, macitentan and tadalafil) (N = 123) versus initial double (placebo, macitentan and tadalafil) (N = 124) therapy. The primary endpoint, change from baseline in pulmonary vascular resistance (PVR) at Week 26, did not show a statistically significant difference between the groups, while showing an improvement from baseline in both treatment groups (relative reduction by |

<div style=\"page-break-after: always\"></div>

|                     | Studies AC-065A308 (TRITON) and AC-065A404 (TRACE). AC-065A308 (TRITON) study was a randomized, double-blind, placebo-controlled, parallel-group, Phase 3b, efficacy and safety study comparing triple oral combination therapy (selexipag, macitentan, tadalafil) with double oral combination therapy (placebo, macitentan, tadalafil) in newly diagnosed, treatment-naïve participants with PAH. The AC-065A404 (TRACE) study was a randomized, double-blind, placebo-controlled, parallel-group, exploratory Phase 4 study in participants with PAH to assess the effect of selexipag on daily life physical activity and participant's self-reported symptoms and their impacts. The package leaflet is updated accordingly. A revised RMP version 9.2 was provided as part of the application. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |            |                       | 54% in the initial triple therapy group vs 52% in the initial double therapy group). Over a median follow-up of 2 years, 4 (3.4%) patients in the triple therapy group and 12 (9.4%) patients in the double therapy group died. Section 4.8 of the SmPC was updated to add dyspepsia as a new ADR with frequency 'common' and to include the information that mean absolute changes in haemoglobin at regular visits compared to baseline ranged from - 1.77 to - 1.26 g/dL in the triple therapy group (selexipag, macitentan, tadalafil) compared to - 1.61 to - 1.28 g/dL in the double therapy group (placebo, macitentan and tadalafil). A decrease from baseline in haemoglobin concentration to below 10 g/dL was reported in 19.0% of patients in the triple therapy group and 14.5% in the double therapy group. Anaemia was reported with very common frequency (13.4%) in the triple therapy group compared to common frequency (8.3%) in the double therapy group. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0036             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 07/03/2022 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| PSUSA/10503 /202012 | Periodic Safety Update EU Single assessment - selexipag                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 08/07/2021 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0033             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 09/03/2021 | 26/11/2021 | SmPC, Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| IB/0031             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                        | 17/12/2020   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0030              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 15/10/2020   | 14/12/2020 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Uptravi in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0029             | Update of section 5.1 of the SmPC based on interim survival and safety data from study AC-065A303 a long-term single-arm, open-label study to evaluate the safety and tolerability of selexipag / ACT-293987 in patients with Pulmonary Arterial Hypertension. In addition, the MAH took the opportunity to implement minor editorial changes and update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 10/12/2020   | 26/11/2021 | SmPC and PL                      | A sub-set of patients who participated in the pivotal phase 3 trial for the authorisation of selexipag in pulmonary arterial hypertension (PAH), entered a long-term, uncontrolled open-label extension study. Given that additional PAH treatment was initiated in a proportion of those patients and that there was no control group in the extension study, the survival benefit of selexipag cannot be confirmed from these data. The long-term follow up of selexipag treated patients showed a safety profile similar to that which had been observed in the pivotal clinical study. For more information, please refer to the Summary of Product Characteristics. |
| PSUSA/10503 /201912 | Periodic Safety Update EU Single assessment - selexipag                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 09/07/2020   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IAIN/0027/G         | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging                                                                                                                                                                                                                                                                                                                       | 19/02/2020   | 14/12/2020 | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                     | site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                         |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10503 /201906 | Periodic Safety Update EU Single assessment - selexipag                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 16/01/2020 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                             |
| IA/0026             | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                                                                                                                                                                                 | 12/12/2019 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                               |
| N/0025              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 24/09/2019 | 14/12/2020 | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0022             | Update of Sections 4.2, 4.4 and 4.5 of the SmPC in order to update the safety information based on the final results from study AC-065-117 a listed category 3 study in the RMP which is a clinical pharmacology drug-drug interaction (DDI) study, evaluating the effect of clopidogrel a moderate inhibitor of CYP2C8, on the pharmacokinetics of selexipag and its active metabolite ACT-333679. The package leaflet is updated accordingly. The RMP version 7.0 has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to correct minor discrepancies in the SmPC. | 27/06/2019 | 25/07/2019 | SmPC, Labelling and PL | When Uptravi is co-administered with moderate CYP2C8 inhibitors (e.g., clopidogrel, deferasirox and teriflunomide), reduce the dosing of Uptravi to once daily. If the therapy is not tolerated at a given dose, symptomatic treatment and/or a dose reduction to the next lower dose should be considered. Revert to twice daily dosing frequency of Uptravi when co-administration of moderate CYP2C8 inhibitor is stopped. |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                          |            |            |                        |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/10503 /201812 | Periodic Safety Update EU Single assessment - selexipag                                                                                                                                                                                    | 11/07/2019 | n/a        |                        | PRAC Recommendation - maintenance |
| PSUSA/10503 /201806 | Periodic Safety Update EU Single assessment - selexipag                                                                                                                                                                                    | 17/01/2019 | n/a        |                        | PRAC Recommendation - maintenance |
| N/0021              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                           | 21/11/2018 | 25/07/2019 | PL                     |                                   |
| T/0019              | Transfer of Marketing Authorisation                                                                                                                                                                                                        | 23/08/2018 | 28/09/2018 | SmPC, Labelling and PL |                                   |
| PSUSA/10503 /201712 | Periodic Safety Update EU Single assessment - selexipag                                                                                                                                                                                    | 12/07/2018 | n/a        |                        | PRAC Recommendation - maintenance |
| N/0018              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                           | 09/04/2018 | 07/06/2018 | Labelling and PL       |                                   |
| IA/0017             | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place | 20/03/2018 | n/a        |                        |                                   |
| IA/0015             | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold                                                                                                                                | 21/02/2018 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|                     | compared to the originally approved batch size                                                                                                                                                                                                                                                                                               |            |            |                       |                                                                                                                                                                                                                                                                                                                                           |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0014           | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                                    | 11/01/2018 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                           |
| PSUSA/10503 /201706 | Periodic Safety Update EU Single assessment - selexipag                                                                                                                                                                                                                                                                                      | 11/01/2018 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                         |
| IG/0839             | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                       | 20/11/2017 | 07/06/2018 | SmPC, Annex II and PL |                                                                                                                                                                                                                                                                                                                                           |
| II/0010             | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                         | 14/09/2017 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                           |
| IB/0011             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                       | 16/08/2017 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                           |
| II/0009             | Update of section 4.5 of the SmPC to add information on the effect of selexipag administration on the pharmacokinetics of midazolam, its metabolite 1- hydroxymidazolam and the CYP3A4 metabolism, based on data from the completed clinical pharmacology study AC-065-114, a single-centre, open-label, randomised, two-treatment crossover | 06/07/2017 | 07/06/2018 | SmPC                  | At steady state after up-titration to 1,600 μ g selexipag twice a day, no clinically relevant change in exposure to midazolam, a sensitive intestinal and hepatic CYP3A4 substrate, or its metabolite, 1 hydroxymidazolam, was observed. Concomitant administration of selexipag with CYP3A4 substrates does not require dose adjustment. |

<div style=\"page-break-after: always\"></div>

|                     | Phase 1 study investigating the effect of selexipag on the pharmacokinetics of midazolam and its metabolite 1-hydroxymidazolam in healthy male subjects. An updated RMP (version 5.4) has also been submitted, to add the results of study AC-065- 114, reclassify 'hyperthyroidism' as an important identified risk and update the PASS timelines and protocol versions in accordance with the current EXPOSURE (PASS AC-065A401, observational cohort study of PAH patients newly treated with either Uptravi (selexipag) or any other PAH specific therapy, in clinical practice) protocol (version 3) and the EDUCATE (PASS AC-065A403, evaluation of risk minimisation measures for medication errors with Uptravi during the titration phase in patients with PAH in clinical practice) protocol version 2. This RMP version also includes the changes approved within procedure EMEA/H/C/3774/II/007 regarding the results of the DDI study investigating the pharmacokinetic interactions of selexipag with gemfibrozil and rifampicin. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |            |                     |                                                                                                                                                                        |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10503 /201612 | Periodic Safety Update EU Single assessment - selexipag                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 06/07/2017 | n/a        |                     | PRAC Recommendation - maintenance                                                                                                                                      |
| II/0007             | Update of sections 4.3, 4.4 and 4.5 of the SmPC in order to add information on pharmacokinetic interactions with gemfibrozil and rifampicin in                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 18/05/2017 | 29/06/2017 | SmPC, Labelling and | In the presence of 600 mg gemfibrozil, twice a day, a strong inhibitor of CYP2C8, exposure to selexipag increased approximately 2-fold, whereas exposure to the active |

<div style=\"page-break-after: always\"></div>

|                     | healthy subjects, based on the final clinical study report of the completed clinical pharmacology drug- drug interaction study AC-065-113. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update information on the hydrolysis of selexipag based on data from the previously submitted absolute bioavailability study AC-065-110, make minor amendments to sections 5.1 and 5.2 of the SmPC and to bring the PI in line with the latest QRD template version 10. An updated version of the RMP (version 5.3) was also submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            | PL                     | metabolite, the major contributor to efficacy, increased approximately 11-fold. Concomitant administration of Uptravi with strong inhibitors of CYP2C8 (e.g., gemfibrozil) is contraindicated. The effect of moderate inhibitors of CYP2C8 (e.g., clopidogrel, deferasirox, teriflunomide) on the exposure to selexipag and its active metabolite has not been studied. An adjustment of the dose of Uptravi should be considered in case a moderate inhibitor of CYP2C8 is coadministered or discontinued. A potential pharmacokinetic interaction with moderate inhibitors of CYP2C8 cannot be excluded. In the presence of 600 mg rifampicin, once a day, an inducer of CYP2C8 (and UGT enzymes), the exposure to selexipag did not change, whereas exposure to the active metabolite was reduced by half. Dose adjustment of selexipag may be required with concomitant administration of inducers of CYP2C8 (e.g., rifampicin, carbamazepine,   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0006           | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 13/01/2017 | 29/06/2017 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| PSUSA/10503 /201606 | Periodic Safety Update EU Single assessment - selexipag                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 12/01/2017 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0005             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 05/01/2017 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|         | manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                 | (excluding         |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------|
| N/0001  | Update of the package leaflet to reflect the approved SmPC contraindication of 'Cerebrovascular events (e.g. transient ischaemic attack, stroke) within the last 3 months', and corrections were made to the patient titration guide at the end of the package leaflet. In addition the MAH took the opportunity to make corrections in the Labelling section 5 'Method and Route(s) of Administration' of the Bulgarian, Czech, Danish, Estonian, Slovenian, German and French labelling in line with the English version, and made linguistic amendments in the French, Greek and Swedish labelling, package leaflet and titration guide. Minor change in labelling or package leaflet not | 19/09/2016 | 29/06/2017 | PL              | connected with the |
| IG/0720 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 16/08/2016 | 29/06/2017 | Annex II and PL |                    |